Literature DB >> 28697916

Treatments for opioid use disorder among pregnant and reproductive-aged women.

Dennis J Hand1, Vanessa L Short2, Diane J Abatemarco2.   

Abstract

The increased prevalence of opioid use disorder and access to medical insurance is subsequently increasing the likelihood that medical professionals will encounter individuals with opioid use disorder. Sharp increases in opioid use disorder among women mean that obstetricians, gynecologists, and other reproductive medicine providers may be especially likely to encounter such patients. Medical professionals' understanding of treatment for opioid use disorder and their roles in their patients' treatment may increase referrals to treatment, reduce stigma, and improve the quality of medical care. Treatment for opioid use disorder falls into four overlapping domains: medication management, medical care, behavioral/mental health care, and psychosocial support. In this review, we discuss these domains with an emphasis on pregnant women and women of reproductive age. Treatment for opioid use disorder is most effective when all providers coordinate care in an informed, nonjudgmental, patient-centered approach.
Copyright © 2017 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; medication-assisted treatment; methadone; opioid; substance use disorder

Mesh:

Substances:

Year:  2017        PMID: 28697916     DOI: 10.1016/j.fertnstert.2017.06.011

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  5 in total

1.  Saving time, signaling trust: Using the PROMOTE self-report screening instrument to enhance prenatal care quality and therapeutic relationships.

Authors:  Heidi Preis; Clare Whitney; Christina Kocis; Marci Lobel
Journal:  PEC Innov       Date:  2022-03-23

2.  Implementing a Learning Collaborative Framework for States Working to Improve Outcomes for Vulnerable Populations: The Opioid Use Disorder, Maternal Outcomes, and Neonatal Abstinence Syndrome Initiative Learning Community.

Authors:  Charlan D Kroelinger; Donna Addison; Mirelys Rodriguez; Marion E Rice; Meghan T Frey; Hadley R Hickner; Mary Kate Weber; Trish Mueller; Alisa Velonis; Keriann Uesugi; Lisa Romero; Sanaa Akbarali; Natalie Foster; Jean Y Ko; Ellen Pliska; Christine Mackie; Shanna Cox; S Nicole Fehrenbach; Wanda D Barfield
Journal:  J Womens Health (Larchmt)       Date:  2020-03-13       Impact factor: 2.681

3.  Support Models for Addiction Related Treatment (SMART) for pregnant women: Study protocol of a cluster randomized trial of two treatment models for opioid use disorder in prenatal clinics.

Authors:  Ariadna Forray; Amanda Mele; Nancy Byatt; Amalia Londono Tobon; Kathryn Gilstad-Hayden; Karen Hunkle; Suyeon Hong; Heather Lipkind; David A Fiellin; Katherine Callaghan; Kimberly A Yonkers
Journal:  PLoS One       Date:  2022-01-13       Impact factor: 3.240

4.  Motherhood, pregnancy and gateways to intervene in substance use disorder.

Authors:  Sugy Choi; Michael D Stein; Julia Raifman; David Rosenbloom; Jack A Clark
Journal:  Health Soc Care Community       Date:  2021-08-07

5.  Pregnancy Outcomes in Maternal Neuropsychiatric Illness and Substance Abuse.

Authors:  Severine Bartel; Serban Dan Costa; Siegfried Kropf; Anke Redlich; Anke Rissmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-11-27       Impact factor: 2.915

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.